Valuation: Immatics N.V.

Market Cap 1.32B 1.16B 1.07B 986M 1.87B 126B 1.9B 12.75B 5.01B 62.16B 4.97B 4.86B 214B P/E 2026 *
-4.7x
P/E 2027 * -5.13x
Enterprise Value 1.14B 994M 917M 847M 1.61B 108B 1.63B 10.96B 4.3B 53.41B 4.27B 4.18B 184B EV / Sales 2026 *
24.2x
EV / Sales 2027 * 22.5x
Free-Float
74.82%
Yield 2026 *
-
Yield 2027 * -
1 day-2.81%
1 week-2.71%
Current month-4.44%
1 month+3.20%
3 months-7.19%
6 months+5.68%
Current year-7.81%
1 week 9.4
Extreme 9.4
10.89
1 month 9
Extreme 9
10.89
Current year 8.55
Extreme 8.55
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 2018-12-31
Director of Finance/CFO 57 2025-09-30
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 51 2020-06-30
Chairman 70 2012-09-30
Director/Board Member 72 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

48,000 0.0358%
06-15Free

Director

48,000 0.0358%
06-15Free

Chairman

48,000 0.0358%
Change 5-day change 1-year change 3-year change Capi.($)
-2.81%-2.71%+62.14%-13.80% 1.32B
+1.84%-0.66%+59.82%+94.48% 54.88B
+0.73%-5.36%+57.86%+131.26% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
-1.69%-1.27%+39.51%-8.30% 19.87B
+0.50%+2.71%+36.81%-27.44% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.42%-3.72%+47.02%+635.77% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average -1.56%-0.52%+52.30%+182.14% 24.29B
Weighted average by Cap. -0.60%-1.46%+50.61%+172.21%

Financials

2026 *2027 *
Net sales 47.04M 41.15M 37.95M 35.05M 66.51M 4.49B 67.63M 453M 178M 2.21B 177M 173M 7.6B 49.11M 42.96M 39.62M 36.6M 69.44M 4.68B 70.61M 473M 186M 2.31B 184M 180M 7.93B
Net income -278M -244M -225M -207M -394M -26.55B -400M -2.68B -1.05B -13.08B -1.05B -1.02B -44.97B -278M -244M -225M -208M -394M -26.56B -400M -2.68B -1.05B -13.08B -1.05B -1.02B -44.98B
Net Debt -186M -163M -150M -139M -263M -17.75B -268M -1.79B -705M -8.75B -699M -684M -30.07B -219M -192M -177M -163M -310M -20.92B -315M -2.11B -831M -10.31B -824M -806M -35.44B
Logo Immatics N.V.
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Employees
678
Date Price Change Volume
26-07-10 US$9.680 -2.81% 264,070
26-07-09 US$9.960 -0.20% 280,585
26-07-08 US$9.980 -2.73% 448,757
26-07-07 US$10.26 +2.70% 401,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.680USD
Average target price
18.89USD
Spread / Average Target
+95.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock